



# Formulary Updates

January 2016

<b>TRADE NAME (generic name) or generic name</b>	<b>Brand/Generic</b>	<b>Description of Change</b>
ACTIMMUNE (interferon gamma-1b inj 100 mcg/0.5ml (2000000 unit/0.5ml))	Brand	Addition
DAKLINZA (daclatasvir dihydrochloride tab 30 mg (base equivalent))	Brand	Addition
DAKLINZA (daclatasvir dihydrochloride tab 60 mg (base equivalent))	Brand	Addition
FINACEA (azelaic acid foam 15%)	Brand	Addition
IXINITY (coagulation factor ix (recombinant) for inj 1000 unit)	Brand	Addition
IXINITY (coagulation factor ix (recombinant) for inj 1500 unit)	Brand	Addition
IXINITY (coagulation factor ix (recombinant) for inj 500 unit)	Brand	Addition
NOXAFIL (posaconazole tab delayed release 100 mg)	Brand	Addition
SPIRIVA RESPIMAT (tiotropium bromide monohydrate inhal aerosol 1.25 mcg/act)	Brand	Addition
ZYVOX (linezolid tab 600 mg)	Brand	Removal – generics available

A division of Health Care Service Corporation, a Mutual Legal Reserve Company, an independent Licensee of the Blue Cross Blue Shield Association. Blue Cross and Blue Shield of Illinois (BCBSIL) contracts with Prime Therapeutics to provide pharmacy benefit management, home delivery pharmacy services and specialty pharmacy services. BCBSIL, as well as several other independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics LLC.